The most likely and least interesting licensing
strategy will be to simply approach each of the owners of the most popular products and offer them a license for their specific
product. Like for infant fluoride, approach Mead Johnson (Poly-Vi-Flor); for acetaminophen, approach McNeil (Tylenol), etc.
These people have worked long and hard to develop and maintain their good products, and deserve the first shot at any new
changes. In some cases (like Mead), they have helped us with things like making our prototype droppers, answering questions,
etc.

Let’s take a quick look at one of the owners,
Pfizer. The advantages of Pfizer as a licensee:

They are very interested in “product
enhancements” – features they can add to drugs that are going off patent very soon.A good example is their antibiotic Zithromax. It will go off patent in less than a year (11-05). It would
be an ideal candidate for dosing by weight (they have done it already in Belgium, see the world list on inside cover page).
They have one enhancement (at least) on Zithromax so far, a “sustained release” version under patent.(See WSJ articles 8-23-04, 12-1-04.)

They even have a separate group that
looks for things just like OptiDose:

If we succeeded in giving Pfizer a
good enhancement on Zithromax, it would almost surely be the biggest and most immediate value we could create with the patent.
The longer and broader prospects would also be good – Pfizer has many other products facing generic competition very
soon.

If there is no interest from the owners, then we
can look at some other strategies. Here is a fun list if you want to look.